Jpmorgan Chase & CO Dbv Technologies S.A. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Shares
1 transactions
Others Institutions Holding DBVT
# of Institutions
2Shares Held
3.2KCall Options Held
0Put Options Held
0About DBV Technologies S.A.
- Ticker DBVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,776,992
- Market Cap $95.8M
- Description
- DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...